Clinical trial
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry…
NCT00429936 · Sirion Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT00429936 |
|---|---|
| Title | Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration |
| Official title | A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration |
| Lead sponsor | Sirion Therapeutics, Inc., Industry |
| Collaborators | ReVision Therapeutics, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Geographic Atrophy, Dry Age Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | Fenretinide |
| Enrollment | 245 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Feb 1, 2007 |
| Last update posted | Jun 22, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: